TABLE 3.
Summary of the comparison between the different antisense oligomers
| ASO modality | mRNA hybridization (EMSA) | Inhibition of translation in vitro | Antibacterial activity (MIC, µM)a | acpP depletion (RNA-seq)a | AcpP protein reduction | Outer membrane permeationa | Uptake inside bacteria (MS)a |
|---|---|---|---|---|---|---|---|
| RNA-F | ++ | ++ | >10 | − | − | − | − |
| RNA-OMe | − | − | >10 | − | − | − | − |
| RNA-MOE | ++ | +++ | >10 | − | − | − | − |
| LNA | +++ | +++ | >10 | − | − | − | − |
| DNA-PTO | − | − | >10 | − | − | − | − |
| PMO | + | ++ | 10 | + | + | ++ | + |
| PNA | +++ | +++ | 1.25 | ++ | ++ | ++ | + |
-
(ASO) Antisense oligomer, (EMSA) electrophoretic mobility shift assays, (MIC) minimum inhibitory concentration, (MS) mass-spectrometry, (RNA-F) 2′-fluorinated RNA, (RNA-OMe) 2′-methylated RNA, (RNA-MOE) 2′-methoxyethylated RNA, (LNA) 2′–4′-locked RNA, (PTO) phosphorothioate, (PMO) phosphorodiamidate morpholino, (PNA) peptide nucleic acid.
-
aThe ASO was conjugated to the carrier peptide. Effect strength is represented by additional (+) signs.
